SAB Biotherapeutics, Inc. SABS
SAB Biotherapeutics, Inc. (Nasdaq: SABS) is an endocrine/women's health drug developer. Its lead program, SAB-142, is in Phase 2 for autoimmune type 1 diabetes (T1D).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SAB-142 | Stage 3 T1D up to two years from diagnosis (PRISE-hATG) | protein/peptide | Phase 3 |
| SAB-142 | autoimmune type 1 diabetes (newly diagnosed Stage 3 T1D) | protein/peptide | Phase 2 |
Recent results and decisions
- Mar 10, 2026positive Additional Phase 1 data: 4 SAB-142 treated T1D patients showed no decrease in C-peptide at Day 120 vs baseline, while the placebo patient declined (exploratory, n=6).
In the T1D cohort (n=6), SAB-142 treated study participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 endocrine/women's health companies
- AbCellera Biologics Inc. ABCL
- MBX Biosciences, Inc. MBX
- Entera Bio Ltd. ENTX
- Vogenx, Inc. VOGX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.